Antiviral Drugs Market is predicted to value over USD 60.5 billion by 2028.

Antiviral drugs are used for treating viral infections like hepatitis, influenza and HIV. These drugs are also used for treating respiratory syncytial virus which is why many companies are testing these drugs over the novel coronavirus, thereby increasing the antiviral drugs market demand. Rising prevalence of such viral infections shall prove to be a crucial factor contributing to the market growth. For example, as per the data provided by the WHO, over 880,000 deaths were caused due to hepatitis B is 2015.

Furthermore, it was predicted that over 255 million patients were diagnosed with hepatitis B virus in 2015. Additionally, as per the weekly U.S. surveillance report on influenza that was published by the CDC, over 12 million flu cases were recorded in 2019. Such factors shall boost the antiviral drugs market growth. Furthermore, extensive research and development of advanced formulations like combination therapy shall further propel the market growth. However, the drug development process is expensive and alternative medicines like homeopathy and naturopathy are gaining significant demands which shall impede the market growth.

Market Segmentation:

By Drug Class

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

By Type

  • Branded
  • Generic

By Application

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others                

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The reverse transcriptase inhibitors segment is predicted to account for the largest antiviral drugs market share owing to its capability of slowing down the infection in an effective manner. Some of the drugs used for treating HIV are Stavudine, Zalcitabine, Zidovudine, Nevirapine, Efavirenz, Didanosine and Etravirine. The branded segment led the market till 2019, but it is the generic segment that is predicted to dominate the market during the forecast period and this can be credited to a rising acceptance of generic drugs in emerging economies like India coupled with a large number of branded drugs with expired patents. Furthermore, many market players consider manufacturing generic drugs over branded ones as the overall process is cheaper, which shall boost the segment growth further. Hepatitis is further divided into hepatitis A, B and C and it is predicted to dominate the market owing to the availability of a large range of antiviral drugs like Tenofovir, Entecavir, Adefovir, Telbivudine and Lamivudine.  The HIV segment is estimated to proliferate with a faster rate during the forecasted timeframe. There has been a strong pipeline of antiviral HIV drugs which shall boost the segment growth. For example, as per the data provided by UNAIDS, over 37 million people were diagnosed with HIV across the world in 2018. Such a rising prevalence shall boost drug development and in turn the market growth.

Regional Analysis:

The North America region is estimated to dominate the market and this is due to the availability of advanced healthcare infrastructure, rising awareness amongst the general population regarding viral diseases and ways in which they can be treated and a strong presence of key market players in the region.

Competitive Landscape:                           

Some of the prominent market players include Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Merck & Co. Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd.

Glenmark shall initiate the combined efficacy testing of two antiviral drugs, Umifenovir and Favipiravir. These drugs have a different set of action mechanism individually, but Glenmark is trying to demonstrate the improvements they can possibly show by combining and can help in tackling high patient count who are still in the early COVID-19 stages by improving their antiviral efficacy.

FutureWise Key Takeaways:

  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth

Objectives of the Study:

  • To provide with an exhaustive analysis on the global antiviral drugs market by type, by drug class, by application and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com


Need Assistance


UK : +44 141 628 9353
US : +1 347 709 4931


Contact Sales

What you get

  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included

  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics